Palliative care in dermatooncology - Current practice in German dermatooncological centers and specialist offices.
care planning
dermato-oncology
palliative care
skin cancer center
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
04 Jul 2024
04 Jul 2024
Historique:
received:
24
08
2023
accepted:
26
03
2024
medline:
5
7
2024
pubmed:
5
7
2024
entrez:
5
7
2024
Statut:
aheadofprint
Résumé
Dermato-oncology patients are often treated in certified skin cancer centers or dermato-oncological specialist offices. Especially in higher tumor stages, patients develop symptoms, either disease-related or due to therapy-related side effects, requiring treatment. Despite a markedly improved prognosis since the introduction of targeted therapies and immunotherapies, advance care planning is required in progressive disease. It is unclear how palliative care of skin cancer patients is currently organized in dermato-oncology. In a nationwide survey, all certified skin cancer centers and dermato-oncological specialist offices in Germany were contacted and asked to participate in this anonymized survey. Overall, 45 responses (42%) were received. The majority (98%) of the respondents screen the patients on a regular basis for distressing symptoms, and all centers are connected to palliative medical care providers. Only 5% of the medical staff members have the additional qualification "palliative medicine". In 68% of the participating institutions, the opportunity for care planning is offered to patients. For 89%, palliative care is relevant for everyday work, and 82% desire more research opportunities on this topic. This survey has shown that palliative care plays a major role in dermato-oncological work. Given that only a small proportion of the staff have received specialized training in palliative care, however, an increase of this proportion would be desirable for comprehensive care.
Sections du résumé
BACKGROUND
BACKGROUND
Dermato-oncology patients are often treated in certified skin cancer centers or dermato-oncological specialist offices. Especially in higher tumor stages, patients develop symptoms, either disease-related or due to therapy-related side effects, requiring treatment. Despite a markedly improved prognosis since the introduction of targeted therapies and immunotherapies, advance care planning is required in progressive disease. It is unclear how palliative care of skin cancer patients is currently organized in dermato-oncology.
PATIENTS AND METHODS
METHODS
In a nationwide survey, all certified skin cancer centers and dermato-oncological specialist offices in Germany were contacted and asked to participate in this anonymized survey.
RESULTS
RESULTS
Overall, 45 responses (42%) were received. The majority (98%) of the respondents screen the patients on a regular basis for distressing symptoms, and all centers are connected to palliative medical care providers. Only 5% of the medical staff members have the additional qualification "palliative medicine". In 68% of the participating institutions, the opportunity for care planning is offered to patients. For 89%, palliative care is relevant for everyday work, and 82% desire more research opportunities on this topic.
CONCLUSIONS
CONCLUSIONS
This survey has shown that palliative care plays a major role in dermato-oncological work. Given that only a small proportion of the staff have received specialized training in palliative care, however, an increase of this proportion would be desirable for comprehensive care.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
Références
Erdmann F, Spix C, Katalinic A, et al. Krebs in Deutschland für 2017/2018. Robert Koch‐Institut; 2021.
Jenkins RW, Fisher DE. Treatment of Advanced Melanoma in 2020 and Beyond. J Invest Dermatol. 2021;141(1):23‐31.
Volberg C, Schrade S, Heers H, et al. End‐of‐life wishes and care planning for patients with advanced skin cancer. J Dtsch Dermatol Ges. 2023;21(10):1148‐1155.
Magin S. Die Integration von Spiritualität ins Gesundheitswesen – Überlegungen zum biopsychosozial‐spirituellen Modell. Spiritual Care. 2022;11(2):165‐166.
Richmond C. Dame Cicely Saunders. BMJ. 2005;331(7510):238‐238.
Volberg C, Wulf H, Schubert AK. Schmerztherapie in der Palliativmedizin. Anästhesiol Intensivmed Notfallmed Schmerzther. 2023;58(02):95‐110.
Sullivan DR, Chan B, Lapidus JA, et al. Association of Early Palliative Care Use With Survival and Place of Death Among Patients With Advanced Lung Cancer Receiving Care in the Veterans Health Administration. JAMA Oncol. 2019;5(12):1702.
Temel JS, Greer JA, Muzikansky A, et al. Early Palliative Care for Patients with Metastatic Non‐Small‐Cell Lung Cancer. N Engl J Med. 2010;363(8):733‐742.
Prütz F, Saß AC. Daten zur Palliativversorgung in Deutschland: Welche Datenquellen gibt es, und was sagen sie aus? Bundesgesundheitsbl. 2017;60(1):26‐36.
Forschner A, Loquai C, Meiss F, et al. Gibt es eine Überbehandlung von Melanompatienten am Ende ihres Lebens? Ergebnisse einer multizentrischen Studie an 193 Melanompatienten. J Dtsch Dermatol Ges. 2021;19(9):1297‐1306.
Michalsen A, Neitzke G, Dutzmann J, et al. Überversorgung in der Intensivmedizin: erkennen, benennen, vermeiden: Positionspapier der Sektion Ethik der DIVI und der Sektion Ethik der DGIIN. Med Klin Intensivmed Notfmed. 2021;116(4):281‐294.
§ 132g Sozialgesetzbuch (SGB) Fünftes Buch (V). Available from: https://www.gesetze-im-internet.de/sgb_5/__132g.html [Last accessed August 19, 2023].
Brinkman‐Stoppelenburg A, Rietjens JA, van der Heide A. The effects of advance care planning on end‐of‐life care: A systematic review. Palliat Med. 2014;28(8):1000‐1025.
Leitlinienprogramm Onkologie, ed. Erweiterte S3‐Leitlinie Palliativmedizin für Patienten mit einer nicht‐heilbaren Krebserkrankung: Langversion 2.0 – August 2019, AWMF‐Registernummer: 128/001‐OL: Leitlinie (Langversion). Kohlhammer; 2019.
S3‐Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms – AWMF‐Register‐Nummer: 032/024OL.
Erhebungsbogen Hautkrebszentren. Stand 31.08.2022, Version J2. Available from: https://www.onkozert.de/organ/haut/ [Last accessed July 25, 2023].
Ulrich C, Hillen U, Gutzmer R. Dermatoonkologie. Hautarzt. 2014;65(7):580‐581.
Ugurel S, Röhmel J, Ascierto PA, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies – update 2017. Eur J Cancer. 2017;83:247‐257.
Becker G, Hatami I, Xander C, et al. Palliative Cancer Care: An Epidemiologic Study. J Clin Oncol. 2011;29(6):646‐650.
Müller‐Busch HC. Kurze Geschichte der Palliativmedizin. In: Schnell MW, Schulz‐Quach C, eds. Basiswissen Palliativmedizin. Springer Berlin Heidelberg; 2019:3‐8.
Bundesärztekammer. Ärztestatistik zum 31.Dezember 2022. Published online December 31, 2022. Available from: https://www.bundesaerztekammer.de/fileadmin/user_upload/BAEK/Ueber_uns/Statistik/Aerztestatistik_2022_09062023.pdf [Last accessed July 25, 2023].
Wagner B, Meffert C, Becker G. Verfügbarkeit und Integration von Palliativmedizin an zertifizierten Lungenkrebszentren. Pneumologie. 2015;69(04):218‐224.
Smith TJ, Temin S, Alesi ER, et al. American Society of Clinical Oncology Provisional Clinical Opinion: The Integration of Palliative Care Into Standard Oncology Care. J Clin Oncol. 2012;30(8):880‐887.
Waller A, Sanson‐Fisher R, Zdenkowski N, et al. The Right Place at the Right Time: Medical Oncology Outpatients’ Perceptions of Location of End‐of‐Life Care. J Natl Compr Canc Netw. 2018;16(1):35‐41.
Seifart C, Nagelschmidt K, von Blanckenburg P. Barrieren für Gespräche über Tod und Sterben in der Medizin. Anästhesiol Intensivmed Notfallmed Schmerzther. 2020;55(05):334‐339.
Heers H, Gschnell M, Schrade S, et al. End of life care: Preferences of patients with advanced urologic and dermatologic malignancies. J Clin Oncol. 2023;41(16_suppl):e24006‐e24006.
Nagelschmidt K, Leppin N, Seifart C, Rief W, et. al. Systematic mixed‐method review of barriers to end‐of‐life communication in the family context. BMJ Support Palliat Care. 2021;11(3):253‐263.
Mesters I, van den Borne H, McCormick L, et al. Openness to discuss cancer in the nuclear family: scale, development, and validation. Psychosom Med. 1997;59(3):269‐279.
Keeley MP. “Turning toward death together”: The functions of messages during final conversations in close relationships. J Soc Pers Relat. 2007;24(2):225‐253.
Yamashita R, Arao H, Takao A, et al. Unfinished Business in Families of Terminally Ill With Cancer Patients. J Pain Symptom Manage. 2017;54(6):861‐869.
Stanze H, Nauck F. Behandlung im Voraus Planen – ein “Advance Care Planning”‐Konzept für Deutschland. Therapeutische Umschau. 2022;79(1):3‐8.
§ 132g Abs. 3 SGB V. Published online December 13, 2017. Available from: https://www.gkv‐spitzenverband.de/media/dokumente/krankenversicherung_1/hospiz_palliativversorgung/versorgungsplanung/Vereinbarung_nach_132g_Abs_3_SGBV_ueber_Inhalte_und_Anforderungen_der_gesundheitlichen_Versorgungsplanung.pdf [Last accessed July 30 2023].
Petri S, Zwißler B, In der Schmitten J, Feddersen B. [Advance Care Planning‐further development of the patient advance directive : What the specialist in internal medicine must know]. Internist (Berl). 2022;63(5):533‐544.
Richter‐Kuhlmann E. Advance Care Planning: Bislang wenig gelebtes Konzept. Dtsch Arztebl. 2019;116(50):A‐2342.